Yosef Landesman

6.8k total citations
171 papers, 3.2k citations indexed

About

Yosef Landesman is a scholar working on Molecular Biology, Oncology and Hematology. According to data from OpenAlex, Yosef Landesman has authored 171 papers receiving a total of 3.2k indexed citations (citations by other indexed papers that have themselves been cited), including 144 papers in Molecular Biology, 49 papers in Oncology and 30 papers in Hematology. Recurrent topics in Yosef Landesman's work include Nuclear Structure and Function (94 papers), Cancer-related Molecular Pathways (31 papers) and RNA Research and Splicing (25 papers). Yosef Landesman is often cited by papers focused on Nuclear Structure and Function (94 papers), Cancer-related Molecular Pathways (31 papers) and RNA Research and Splicing (25 papers). Yosef Landesman collaborates with scholars based in United States, Italy and Belgium. Yosef Landesman's co-authors include Sharon Shacham, Erkan Baloglu, William Senapedis, Michael Kauffman, Trinayan Kashyap, Marsha Crochiere, Dilara McCauley, Asfar S. Azmi, Amro Aboukameel and Boris Klebanov and has published in prestigious journals such as Journal of Clinical Oncology, The Journal of Cell Biology and Blood.

In The Last Decade

Yosef Landesman

164 papers receiving 3.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Yosef Landesman United States	33	2.5k	935	640	340	303	171	3.2k
Péter Sandy United States	17	3.0k 1.2×	994 1.1×	629 1.0×	203 0.6×	429 1.4×	27	3.5k
Amanda L. Christie United States	21	1.6k 0.6×	1.0k 1.1×	624 1.0×	244 0.7×	230 0.8×	34	2.4k
Joseph Gera United States	28	2.4k 1.0×	592 0.6×	474 0.7×	221 0.7×	396 1.3×	60	3.0k
Geoffrey W. Krystal United States	32	1.9k 0.7×	970 1.0×	634 1.0×	404 1.2×	292 1.0×	50	3.2k
Josée Hébert Canada	33	2.2k 0.9×	550 0.6×	947 1.5×	218 0.6×	389 1.3×	93	3.1k
John F. Lyons United States	32	2.7k 1.1×	1.3k 1.4×	577 0.9×	454 1.3×	551 1.8×	81	4.3k
Matthew R. Janes United States	15	2.2k 0.9×	594 0.6×	243 0.4×	251 0.7×	273 0.9×	26	2.7k
Marc R. Mansour United Kingdom	26	1.9k 0.8×	557 0.6×	651 1.0×	118 0.3×	347 1.1×	59	2.9k
Anne M. Øyan Norway	37	1.6k 0.6×	809 0.9×	341 0.5×	410 1.2×	769 2.5×	75	2.9k
Joseph M. Amann United States	28	1.8k 0.7×	825 0.9×	346 0.5×	605 1.8×	426 1.4×	53	2.7k

Countries citing papers authored by Yosef Landesman

Since Specialization

Citations

This map shows the geographic impact of Yosef Landesman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yosef Landesman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yosef Landesman more than expected).

Fields of papers citing papers by Yosef Landesman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yosef Landesman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yosef Landesman. The network helps show where Yosef Landesman may publish in the future.

Co-authorship network of co-authors of Yosef Landesman

This figure shows the co-authorship network connecting the top 25 collaborators of Yosef Landesman. A scholar is included among the top collaborators of Yosef Landesman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yosef Landesman. Yosef Landesman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Landesman, Yosef, Didier Desmaële, Françoise Piguet, et al.. (2025). Therapeutic potential of siRNA PMP22-SQ nanoparticles for Charcot-Marie-Tooth 1A neuropathy in rodents and non-human primates. International Journal of Pharmaceutics. 671. 125234–125234. 2 indexed citations

Chow, Frances, Michael E. Berens, Sharon Tamir, et al.. (2023). 421 A Phase 1 and Randomized Phase 2 Clinical Trial of Selinexor and Temozolomide in Recurrent Glioblastoma Among Adults: The Product of a Successful Team Science Approach. Journal of Clinical and Translational Science. 7(s1). 126–126.

Li, Shirong, Jing Fu, Christopher J. Walker, et al.. (2023). Dual targeting of protein translation and nuclear protein export results in enhanced antimyeloma effects. Blood Advances. 7(12). 2926–2937. 6 indexed citations

Johnson, Peter, Yosef Landesman, Mark S. Cragg, et al.. (2023). XPO1 inhibition sensitises CLL cells to NK cell mediated cytotoxicity and overcomes HLA-E expression. Leukemia. 37(10). 2036–2049. 12 indexed citations

Pianigiani, Giulia, Federica Mezzasoma, Francesca Rocchio, et al.. (2022). Prolonged XPO1 inhibition is essential for optimal antileukemic activity in NPM1-mutated AML. Blood Advances. 6(22). 5938–5949. 22 indexed citations

Lassman, Andrew B., Patrick Y. Wen, Martin J. van den Bent, et al.. (2021). A Phase II Study of the Efficacy and Safety of Oral Selinexor in Recurrent Glioblastoma. Clinical Cancer Research. 28(3). 452–460. 40 indexed citations

Shain, Kenneth H., Rafael Renatino Canevarolo, Mark B. Meads, et al.. (2020). Characterization of Synergistic Selinexor Combinations of Dexamethasone, Pomalidomide, Elotuzumab and Daratumumab in Primary MM Samples Ex Vivo. Blood. 136(Supplement 1). 29–30. 1 indexed citations

Sierra, Laura, Lyazat Kurenbekova, Ryan L. Shuck, et al.. (2020). Targeting PAK4 Inhibits Ras-Mediated Signaling and Multiple Oncogenic Pathways in High-Risk Rhabdomyosarcoma. Cancer Research. 81(1). 199–212. 29 indexed citations

DeSisto, John, Patrick Flannery, Amrita Pathak, et al.. (2019). Exportin 1 Inhibition Induces Nerve Growth Factor Receptor Expression to Inhibit the NF-κB Pathway in Preclinical Models of Pediatric High-Grade Glioma. Molecular Cancer Therapeutics. 19(2). 540–551. 18 indexed citations

10.

Ming, Mei, Wenjun Wu, Bingqing Xie, et al.. (2018). XPO1 Inhibitor Selinexor Overcomes Intrinsic Ibrutinib Resistance in Mantle Cell Lymphoma via Nuclear Retention of IκB. Molecular Cancer Therapeutics. 17(12). 2564–2574. 36 indexed citations

11.

Wang, Y. Lynn, Mei Ming, Bingqing Xie, et al.. (2017). XPO1 Inhibitor Selinexor Overcomes Ibrutinib Resistance in Mantle Cell Lymphoma Via Nuclear Retention of IκB. Blood. 130. 3837–3837. 1 indexed citations

12.

Tyler, Paul, Boris Klebanov, Trinayan Kashyap, et al.. (2017). Clinical Dosing Regimen of Selinexor Maintains Normal Immune Homeostasis and T-cell Effector Function in Mice: Implications for Combination with Immunotherapy. Molecular Cancer Therapeutics. 16(3). 428–439. 28 indexed citations

13.

Farren, Matthew R., Reena Shakya, Gregory Young, et al.. (2017). The Exportin-1 Inhibitor Selinexor Exerts Superior Antitumor Activity when Combined with T-Cell Checkpoint Inhibitors. Molecular Cancer Therapeutics. 16(3). 417–427. 23 indexed citations

14.

Aboukameel, Amro, Irfana Muqbil, William Senapedis, et al.. (2016). Novel p21-Activated Kinase 4 (PAK4) Allosteric Modulators Overcome Drug Resistance and Stemness in Pancreatic Ductal Adenocarcinoma. Molecular Cancer Therapeutics. 16(1). 76–87. 74 indexed citations

15.

Vercruysse, Thomas, Jolien De Bie, Jasper E. Neggers, et al.. (2016). The Second-Generation Exportin-1 Inhibitor KPT-8602 Demonstrates Potent Activity against Acute Lymphoblastic Leukemia. Clinical Cancer Research. 23(10). 2528–2541. 53 indexed citations

16.

Ranganathan, Parvathi, Trinayan Kashyap, Xueyan Yu, et al.. (2016). XPO1 Inhibition using Selinexor Synergizes with Chemotherapy in Acute Myeloid Leukemia by Targeting DNA Repair and Restoring Topoisomerase IIα to the Nucleus. Clinical Cancer Research. 22(24). 6142–6152. 67 indexed citations

17.

Malafa, Mokenge P., Domenico Coppola, Kazim Husain, et al.. (2015). Selective Nuclear Export Inhibitor KPT-330 Enhances the Antitumor Activity of Gemcitabine in Human Pancreatic Cancer. Molecular Cancer Therapeutics. 14(7). 1570–1581. 50 indexed citations

18.

Chan, Carlos H.F., Tristan Penson, Yosef Landesman, et al.. (2015). XPO1 Inhibition Enhances Radiation Response in Preclinical Models of Rectal Cancer. Clinical Cancer Research. 22(7). 1663–1673. 36 indexed citations

19.

Cheng, Yan, Michael P. Holloway, Kevin T. Nguyen, et al.. (2014). XPO1 (CRM1) Inhibition Represses STAT3 Activation to Drive a Survivin-Dependent Oncogenic Switch in Triple-Negative Breast Cancer. Molecular Cancer Therapeutics. 13(3). 675–686. 83 indexed citations

20.

Chung, Hye Won, Yosef Landesman, William Senapedis, et al.. (2013). CRM1 and BRAF Inhibition Synergize and Induce Tumor Regression in BRAF-Mutant Melanoma. Molecular Cancer Therapeutics. 12(7). 1171–1179. 57 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact